P53 and its co-activator p300 are inversely regulated in the mouse colon in response to carcinogen

Toxicology Letters

Volumn 144, Issue 2, 2003, Pages 213-224

  Aizu, Wataru ^a   Guda, Kishore ^b   Nambiar, Prashant ^b   Xin, Tong ^a   Thibodeau, Michael ^a   Rosenberg, Daniel W ^b   Giardina, Charles ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Azoxymethane; Cancer; Colon carcinogen; P300; P53

Indexed keywords

AZOXYMETHANE; CARCINOGEN; PROTEIN BAX; PROTEIN P300; PROTEIN P53;

ACUTE TOXICITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENICITY; CELL SUBPOPULATION; COLON; COLON CARCINOGENESIS; CONTROLLED STUDY; CRYPT CELL; GENE ACTIVATION; GENE EXPRESSION REGULATION; IMMUNOCYTOCHEMISTRY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN STABILITY; TRANSCRIPTION REGULATION;

EID: 0041631078     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(03)00221-2     Document Type: Article

References (53)

1. Amundson S.A., Myers T.G., Fornace A.J. Jr. Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene. 17:1998;3287-3299.
2. Attardi L.D., Reczek E.E., Cosmas C., Demicco E.G., McCurrach M.E., Lowe S.W., Jacks T. PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev. 14:2000;704-718.
3. Bandyopadhyay D., Okan N.A., Bales E., Nascimento L., Cole P.A., Medrano E.E. Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes. Cancer Res. 62:2002;6231-6239.
4. Barak Y., Juven T., Haffner R., Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J. 12:1993;461-468.
5. Bissonnette N., Wasylyk B., Hunting D.J. The apoptotic and transcriptional transactivation activities of p53 can be dissociated. Biochem. Cell. Biol. 75:1997;351-358.
6. Cho S., Tian Y., Benjamin T.L. Binding of p300/CBP co-activators by polyoma large T antigenm. J. Biol. Chem. 276:2001;33533-33539.
7. Colman M.S., Afshari C.A., Barrett J.C. Regulation of p53 stability and activity in response to genotoxic stress. Mutat Res. 462:2000;179-188.
8. Earley S., Resta T.C. Estradiol attenuates hypoxia-induced pulmonary endothelin-1 gene expression. Am. J. Phys. Lung Cell. Mol. Physiol. 283:2002;L86-L93.
9. Eischen C.M., Rehg J.E., Korsmeyer S.J., Cleveland J.L. Loss of Bax alters tumor spectrum and tumor numbers in ARF-deficient mice. Cancer Res. 62:2002;2184-2191.
10. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
11. Erdman S.H., Wu H.D., Hixson L.J., Ahnen D.J., Gerner E.W. Assessment of mutations in Ki-ras and p53 in colon cancers from azoxymethane- and dimethylhydrazine-treated rats. Mol. Carcinog. 19:1997;137-144.
12. Espinosa J.M., Emerson B.M. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol. Cell. 8:2001;57-69.
13. Feil R., Khosla S. Genomic imprinting in mammals: an interplay between chromatin and DNA methylation. Trends Genet. 15:1999;431-435.
14. Gibson P.R., Moeller I., Kagelari O., Folino M., Young G.P. Contrasting effects of butyrate on the expression of phenotypic markers of differentiation in neoplastic and non-neoplastic colonic epithelial cells in vitro. J. Gastroenterol. Hepatol. 7:1992;165-172.
15. Goodman R.H., Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev. 14:2000;1553-1577.
16. Gottlieb T.M., Oren M. p53 and apoptosis. Semin. Cancer Biol. 8:1998;359-368.
17. Grossman S.R. p300/CBP/p53 interaction and regulation of the p53 response. Eur. J. Biochem. 268:2001;2773-2778.
18. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 389:1997;349-352.
19. Gu W., Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 90:1997;595-606.
20. Heerdt B.G., Houston M.A., Augenlicht L.H. Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Cancer Res. 54:1994;3288-3293.
21. Hirose Y., Yoshimi N., Makita H., Hara A., Tanaka T., Mori H. Early alterations of apoptosis and cell proliferation in azoxymethane-initiated rat colonic epithelium. Jpn. J. Cancer Res. 87:1996;575-582.
22. Homaidan F.R., Zhao L., Donovan V., Shinowara N.L., Burakoff R. Separation of pure populations of epithelial cells from rabbit distal colon. Anal. Biochem. 224:1995;134-139.
23. Ijiri K. Apoptosis (cell death) induced in mouse bowel by 1,2-dimethylhydrazine, methylazoxymethanol acetate, and gamma-rays. Cancer Res. 49:1989;6342-6346.
24. Inan M.S., Rasoulpour R.J., Yin L., Hubbard A.K., Rosenberg D.W., Giardina C. The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonic epithelial cell line. Gastroenterology. 118:2000;724-734.
25. Inan M.S., Tolmacheva V., Wang Q.S., Rosenberg D.W., Giardina C. Transcription factor NF-kappaB participates in regulation of epithelial cell turnover in the colon. Am. J. Physiol. Gastrointest. Liver Physiol. 279:2000;G1282-G1291.
26. Ito A., Lai C.H., Zhao X., Saito S., Hamilton M.H., Appella E., Yao T.P. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 20:2001;1331-1340.
27. Kaiser G.C., Polk D.B. Tumor necrosis factor alpha regulates proliferation in a mouse intestinal cell line. Gastroenterology. 112:1997;1231-1240.
28. Kar S., Sakaguchi K., Shimohigashi Y., Samaddar S., Banerjee R., Basu G., Swaminathan V., Kundu T.K., Roy S. Effect of phosphorylation on the structure and fold of transactivation domain of p53. J. Biol. Chem. 277:2002;15579-15585.
29. Karymov M.A., Tomschik M., Leuba S.H., Caiafa P., Zlatanova J. DNA methylation-dependent chromatin fiber compaction in vivo and in vitro: requirement for linker histone. FASEB J. 15:2001;2631-2641.
30. Lakin N.D., Jackson S.P. Regulation of p53 in response to DNA damage. Oncogene. 18:1999;7644-7655.
31. Lijinsky W. The metabolism and cellular interactions of some aliphatic nitrogenous carcinogens. Cancer Lett. 26:1985;33-42.
32. Mariadason J.M., Corner G.A., Augenlicht L.H. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res. 60:2000;4561-4572.
33. McManus K.J., Hendzel M.J. CBP, a transcriptional coactivator and acetyltransferase. Biochem. Cell. Biol. 79:2001;253-266.
34. Nambiar P.R., Giardina C., Guda K., Aizu W., Raja R., Rosenberg D.W. Role of the alternating reading frame (P19)-p53 pathway in an in vivo murine colon tumor model. Cancer Res. 62:2002;3667-3674.
35. Oda E., Ohki R., Murasawa H., Nemoto J., Shibue T., Yamashita T., Tokino T., Taniguchi T., Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 288:2000;1053-1058.
36. Papanikolaou A., Shank R.C., Delker D.A., Povey A., Cooper D.P., Rosenberg D.W. Initial levels of azoxymethane-induced DNA methyl adducts are not predictive of tumor susceptibility in inbred mice. Toxicol. Appl. Pharmacol. 150:1998;196-203.
37. Podolsky D.K. Healing the epithelium: solving the problem from two sides. J. Gastroenterol. 32:1997;122-126.
38. Poizat C., Sartorelli V., Chung G., Kloner R.A., Kedes L. Proteasome-mediated degradation of the coactivator p300 impairs cardiac transcription. Mol. Cell. Biol. 20:2000;8643-8654.
39. Potten C.S., Li Y.Q., O'Connor P.J., Winton D.J. A possible explanation for the differential cancer incidence in the intestine, based on distribution of the cytotoxic effects of carcinogens in the murine large bowel. Carcinogenesis. 13:1992;2305-2312.
40. Pritchard D.M., Jackman A., Potten C.S., Hickman J.A. Chemically-induced apoptosis: p21 and p53 as determinants of enterotoxin activity. Toxicol. Lett. 102-103:1998;19-27.
41. Pritchard D.M., Potten C.S., Hickman J.A. The relationships between p53-dependent apoptosis, inhibition of proliferation, and 5-fluorouracil-induced histopathology in murine intestinal epithelia. Cancer Res. 58:1998;5453-5465.
42. Somasundaram K., El-Deiry W.S. Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region. Oncogene. 14:1997;1047-1057.
43. Speir E., Yu Z.X., Takeda K., Ferrans V.J., Cannon R.O. III. Competition for p300 regulates transcription by estrogen receptors and nuclear factor-kappaB in human coronary smooth muscle cells. Circ. Res. 87:2000;1006-1011.
44. Urnov F.D., Wolffe A.P. Chromatin remodeling and transcriptional activation: the cast (in order of appearance). Oncogene. 20:2001;2991-3006.
45. Velcich A., Palumbo L., Jarry A., Laboisse C., Racevskis J., Augenlicht L. Patterns of expression of lineage-specific markers during the in vitro-induced differentiation of HT29 colon carcinoma cells. Cell Growth Differ. 6:1995;749-757.
46. Vigushin D.M., Coombes R.C. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs. 13:2002;1-13.
47. Vo N., Goodman R.H. CREB-binding protein and p300 in transcriptional regulation. J. Biol. Chem. 276:2001;13505-13508.
48. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature. 408:2000;307-310.
49. Whitehead R.H., VanEeden P.E., Noble M.D., Ataliotis P., Jat P.S. Establishment of conditionally immortalized epithelial cell lines from both colon and small intestine of adult H-2Kb-tsA58 transgenic mice. Proc. Natl. Acad. Sci. USA. 90:1993;587-591.
50. Wilson J.W., Pritchard D.M., Hickman J.A., Potten C.S. Radiation-induced p53 and p21WAF-1/CIP1 expression in the murine intestinal epithelium: apoptosis and cell cycle arrest. Am. J. Pathol. 153:1998;899-909.
51. Yaciuk P., Moran E. Analysis with specific polyclonal antiserum indicates that the E1A-associated 300-kDa product is a stable nuclear phosphoprotein that undergoes cell cycle phase-specific modification. Mol. Cell. Biol. 11:1991;5389-5397.
52. Yao T.P., Oh S.P., Fuchs M., Zhou N.D., Ch'ng L.E., Newsome D., Bronson R.T., Li E., Livingston D.M., Eckner R. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell. 93:1998;361-372.
53. Yuan L.W., Soh J.W., Weinstein I.B. Inhibition of histone acetyltransferase function of p300 by PKCdelta. Biochim. Biophys. Acta. 1592:2002;205-211.